Pulmonology · 2026
Clinical and economic burden of respiratory syncytial virus among adults hospitalised with acute respiratory infections in Portugal.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fonseca Maria João, Reeves Rachel M, Pliakas Triantafyllos, Lopes Rita, Simão Paula, Froes Filipe, Silva Liliana, Coelho Ana, Teixeira Neuza, Castanheira Raquel, Gkalapi Foteini, Marijam Alen, Gavina Cristina
Аннотация
BACKGROUND: Respiratory syncytial virus (RSV) is an important cause of acute respiratory infection (ARI), but its burden in Portuguese adults remains under-investigated.
METHODS: This single-centre retrospective database cohort study examined RSV-ARI hospitalisations in adults aged ≥18 years over six consecutive seasons (2018/19 to 2023/24), a period which includes years impacted by COVID-19 disruptions. Outcomes included the prevalence of RT-PCR-confirmed RSV-ARI among tested ARI admissions, clinical features and adverse outcomes, healthcare resource use and direct costs; outcomes were also described for influenza-ARI to provide context. Analyses were descriptive without any comparison between the groups.
RESULTS: Of 7,125 ARI-hospitalisations 3,011 underwent RSV/influenza testing. The overall prevalence of RT-PCR-confirmed RSV-ARI and influenza-ARI in tested admissions was 8.1% and 20.3%, respectively. The study included 244 RSV-ARI and 612 influenza-ARI admissions, most ≥60 years old; 77.1% of RSV-ARI admissions and 61.4% of influenza-ARI admissions involved high-risk patients with comorbidities. Complications within 90 days were frequent, including acute cardiac events (RSV-ARI, 47.1%; influenza-ARI, 38.2%), respiratory failure (46.3% and 31.5%), pneumonia (34.0% and 22.4%) and acute renal disease (34.0% and 29.3%). All-cause in-hospital mortality was 19.7% for RSV-ARI (influenza-ARI, 12.8%). Mean length of stay for RSV-ARI was 8.5 days (interquartile range ([IQR], 9.7) with a mean cost of €4 757; for influenza-ARI, 7.4 days (IQR 8.9) and €3 537, respectively.
CONCLUSIONS: RSV represents an important cause of ARI-hospitalisation in older adults, especially in those with comorbidities, with a substantial clinical and economic burden, which was similar or higher than influenza (GSK study identifier: VEO-000773).
METHODS: This single-centre retrospective database cohort study examined RSV-ARI hospitalisations in adults aged ≥18 years over six consecutive seasons (2018/19 to 2023/24), a period which includes years impacted by COVID-19 disruptions. Outcomes included the prevalence of RT-PCR-confirmed RSV-ARI among tested ARI admissions, clinical features and adverse outcomes, healthcare resource use and direct costs; outcomes were also described for influenza-ARI to provide context. Analyses were descriptive without any comparison between the groups.
RESULTS: Of 7,125 ARI-hospitalisations 3,011 underwent RSV/influenza testing. The overall prevalence of RT-PCR-confirmed RSV-ARI and influenza-ARI in tested admissions was 8.1% and 20.3%, respectively. The study included 244 RSV-ARI and 612 influenza-ARI admissions, most ≥60 years old; 77.1% of RSV-ARI admissions and 61.4% of influenza-ARI admissions involved high-risk patients with comorbidities. Complications within 90 days were frequent, including acute cardiac events (RSV-ARI, 47.1%; influenza-ARI, 38.2%), respiratory failure (46.3% and 31.5%), pneumonia (34.0% and 22.4%) and acute renal disease (34.0% and 29.3%). All-cause in-hospital mortality was 19.7% for RSV-ARI (influenza-ARI, 12.8%). Mean length of stay for RSV-ARI was 8.5 days (interquartile range ([IQR], 9.7) with a mean cost of €4 757; for influenza-ARI, 7.4 days (IQR 8.9) and €3 537, respectively.
CONCLUSIONS: RSV represents an important cause of ARI-hospitalisation in older adults, especially in those with comorbidities, with a substantial clinical and economic burden, which was similar or higher than influenza (GSK study identifier: VEO-000773).